The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Tisagenlecleucel — the first approved CAR-T-cell therapy: implications for payers and policy makers
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They are genetically modified cytotoxic T cells that target particular cancer-related antigens and were given clinical approval in 2017.323”
From Smart nanoparticles for cancer therapy (2023) · cites this paper as [323]
In the citing paper
“Several viral vector mediated cellular and gene-therapy products, such as Kymriah for CAR-T immunotherapy on lymphoblastic leukemia, have already gained FDA approval.[27]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [27]
Citations
Cites
Prasad, V. K., & Mailankody, S. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3601 · Cited by 532
Self-citationMajhail, N. S., Mau, L., Denzen, E. M., & Arneson, T. J. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.133 · Cited by 143
Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Lamont, E. B., Hayreh, D., Pickett, K. E., Dignam, J. J., List, M. A., Stenson, K. M., Haraf, D. J., Brockstein, B., Sellergren, S. A., & Vokes, E. E. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg035 · Cited by 139
Re: Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?
Munoz, A., & Samet, J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh065 · Cited by 112
FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome
Administration, U. S. F. &. D. (2017) · Case Medical Research · doi:10.31525/fda1-ucm574154.htm · Cited by 28
Research works printed but not linked: 2
- Mitchell, D. Patients For Affordable Drugs launches campaign demanding fair pricing of new Novartis cancer drug. Patients For Affordable Drugs http://www.patientsforaffordabledrugs.org/2017/08/17/patients-for-affordable-drugs-launches-campaign-demanding-fair-pricing-of-new-cancer-drug/ (17 Aug 2017).
- Gilead Sciences, Inc. Gilead Sciences to acquire Kite Pharma for $11.9 billion. Gilead Sciences, Inc. http://www.gilead.com/news/press-releases/2017/8/gilead-sciences-to-acquire-kite-pharma-for-119-billion (28 Aug 2017).
Cited by
Sorted by citations
The evolution of commercial drug delivery technologies
Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 852
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 762
Enabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
Metadata
- Authors
- Prasad, V.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Prasad, Vinay
- ORCID
- Prasad, Vinay
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2017-10-04
- Volume
- 15
- Issue
- 1
- Pages
- 11-12
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2761202053
- Cited by
- 229
- References
- 5
- Citations by year
- 2026: 17 · 2025: 12 · 2024: 27 · 2023: 28 · 2022: 36 · 2021: 31 · 2020: 28 · 2019: 25 · 2018: 24 · 2017: 1
- FWCI
- 9.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- tisagenlecleucel, CAR T-cell therapy, FDA approval, health care costs, drug pricing, health policy, health insurance coverage, treatment toxicity, healthcare logistics
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Immunotherapy, Neoplasms, Receptors, Antigen, T-Cell, Immunotherapy, Adoptive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
